Home Companies Catalysts Deep Dives
VIEW 2 PHASE3 COMPLETED n=1240
Drug: EYLEA · REGN
Study Design
DesignRandomized, double-masked, active-controlled, multicenter (ex-US)
Randomization1:1:1:1
BlindingDouble-masked
Enrollment1240
Duration52 weeks
NCTNCT00637377
Treatment Arms
EYLEA 2mg Q8W 2mg intravitreal Q8W (after 3 monthly loading) n=306
EYLEA 2mg Q4W 2mg intravitreal Q4W n=313
EYLEA 0.5mg Q4W 0.5mg intravitreal Q4W n=311
Ranibizumab 0.5mg Q4W 0.5mg intravitreal Q4W (active control) n=310
Primary Endpoints
[{"id":"view2-vision","name":"Maintained vision at Week 52 (lost <15 letters)","type":"PRIMARY","unit":"%","results":[{"notes":"Non-inferior to ranibizumab. 95.6% vs 94.4%","value":95,"arm_id":"eylea-q8w-view2","arm_name":"EYLEA 2mg Q8W"},{"value":94,"arm_id":"ranibizumab-view2","arm_name":"Ranibizumab Q4W"}],"timepoint":"Week 52","description":"Proportion losing <15 ETDRS letters from baseline. Non-inferiority to monthly ranibizumab. Confirmatory to VIEW 1 (US study)."}]
Efficacy Results
VIEW 2 confirmed VIEW 1: EYLEA Q8W (95.6%) was non-inferior to ranibizumab Q4W (94.4%) for vision maintenance. Pooled VIEW 1+2 analysis led to FDA approval in 2011.
Safety Results
VIEW 2 (n=1240): Similar safety profile to VIEW 1. Conjunctival hemorrhage, eye pain, and IOP increase most common. Endophthalmitis <0.1%.
Assessment
VIEW 2 confirmed VIEW 1 internationally. Together they supported EYLEA global approval. The key is Q8W dosing — half the injection burden of monthly ranibizumab with equivalent outcomes.
Background & Context
International confirmatory study of VIEW 1. Demonstrates EYLEA Q8W is non-inferior across global populations.
Data from Supabase · Updated 2026-03-24